Sanofi announced plans to evolve its business with the creation of five Global Business Units beginning in January 2016.
The General Medicines & Emerging Markets Global Business Unit will consist of Sanofi’s Established Products, Generics, Consumer Healthcare and all pharmaceutical businesses in Emerging Markets.
The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will consist of Sanofi’s medicines in Rare Diseases, Multiple Sclerosis, Oncology and immunology, including the two investigational biologics, sarilumab and dupilumab.
The Diabetes & Cardiovascular Global Business Unit will consist of Sanofi’s Diabetes Care medicines as well as Cardiovascular, which includes alirocumab, currently under review by the U.S. FDA and the European Medicines Agency (EMA).
Sanofi Pasteur and Merial are both Global Business Units and will continue to manage their current portfolios of vaccines and animal health products.
Similar to Research and Development and Industrial Affairs, all functions will be globalized to better serve the Business Units. The composition of the Executive Committee remains unchanged. The leadership roles are effective January 1st, 2016.